Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis

Summary

This study is to evaluate non inferiority of Eurofarma budesonide nasal spary x referral Astrazeneca budesonide. Half patients will receive Eurofarma medication and half patients will receive Astrazeneca medication. There is no placebo group.

Timeline

Start

2016-06

Primary completion

2019-11

Completion

2019-11

Outcome

Outcome not reported

Stopped (Business): “Regulatory strategy”

Drugs

Indications